Nasal spray (Zavegepant) for migraines: a mini-review

Safety, tolerability, and efficacy of zavegepant 10 mg nasal spray for the acute treatment of migraine in the USA: a phase 3, double-blind, randomised, placebo-controlled multicentre trial

(2023) Richard B Lipton et al.   LANCET NEUROLOGY

The global prevalence of headache: an update, with analysis of the influences of methodological factors on prevalence estimates

(2022) Lars Jacob Stovner et al.   JOURNAL OF HEADACHE AND PAIN

Zavegepant nasal spray for the acute treatment of migraine: A Phase 2/3 double‐blind, randomized, placebo‐controlled, dose‐ranging trial

(2022) Robert Croop et al.   HEADACHE

Focus on zavegepant: the first intranasal third-generation gepant

(2022) Damiana Scuteri et al.   Pain Management

Global, regional, and national burden of migraine in 204 countries and territories, 1990 to 2019

(2021) Saeid Safiri et al.   PAIN

Migraine review for general practice

(2021) Antonio L. Aguilar-Shea et al.   Atencion Primaria

Comparison of New Pharmacologic Agents With Triptans for Treatment of Migraine

(2021) Chun-Pai Yang et al.   JAMA Network Open

Efficacy of triptans for the treatment of acute migraines: a quantitative comparison based on the dose-effect and time-course characteristics

(2019) Mengyuan Hou et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

International Classification of Headache Disorders

(2018) Jes Olesen   LANCET NEUROLOGY

The pathophysiology of migraine: implications for clinical management

(2018) Andrew Charles   LANCET NEUROLOGY

Acute Migraine Treatment in Adults

(2015) Werner J. Becker   HEADACHE

The diagnosis and treatment of chronic migraine

(2015) Mark W. Weatherall   Therapeutic Advances in Chronic Disease

Oral Triptans and Nausea: Treatment Considerations in Migraine

(2013) Mark Pierce   HEADACHE

Why pharmacokinetic differences among oral triptans have little clinical importance: a comment

(2010) Anna Ferrari et al.   JOURNAL OF HEADACHE AND PAIN